- The omega-3 prescription drug market is expected to double by 2019.
- ACST's omega-3 prescription drug CaPre is a potential blockbuster.
- ACST's stock price could double in 2014 if its TRIFECTA results, due in June 2014, are positive.
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.